Skip to main content
Figure 1 | BMC Pediatrics

Figure 1

From: Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

Figure 1

The two regimens of dalteparin combination therapy. *Aspirin (ASA) was decreased to 5 mg/kg/day if the patient was afebrile, clinically improving, and/or showed a CRP < 1.0 mg/dL. **Aspirin withdrawn after 1 month of illness unless there were cardiac sequelae. Dalteparin was administered until the patient was afebrile, clinically improving, and/or showed a CRP < 1.0 mg/dL. ***IVIG started on day 4 or 5 of illness (the first illness day was defined as the day of onset of fever >38°C).

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us